BG-12, Biogen Idec's Novel Oral Compound Shown To Significantly Reduced Brain Lesions In Patients With Multiple Sclerosis Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 AM
